Oxford Biomedica PLC/ GB00BDFBVT43 /
9/6/2024 5:21:32 PM | Chg. -3.50 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
327.00GBX | -1.06% | 1,805 Turnover(GBP): 5,891.0350 |
-Bid Size: - | -Ask Size: - | 261.28 mill.GBP | - | - |
GlobeNewswire
3/6
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire
3/5
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire
1/23
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire
1/7
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire
1/3
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
12/4/2023
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire
11/9/2023
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
9/20/2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire
9/20/2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023